ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
07 juil. 2021 08h00 HE
|
ARCA biopharma, Inc.
Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma,...
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
11 mai 2021 16h15 HE
|
ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
03 mai 2021 16h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
18 mars 2021 16h30 HE
|
ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
15 déc. 2020 08h30 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
23 nov. 2020 08h30 HE
|
ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
02 nov. 2020 08h30 HE
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
07 oct. 2020 08h30 HE
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h15 HE
|
ARCA biopharma, Inc.
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...